{"id":998893,"date":"2026-08-28T17:18:02","date_gmt":"2026-08-28T21:18:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trinity-biotech-provides-diagnostics-business-transformation-and-corporate-update\/"},"modified":"2026-08-28T17:18:02","modified_gmt":"2026-08-28T21:18:02","slug":"trinity-biotech-provides-diagnostics-business-transformation-and-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trinity-biotech-provides-diagnostics-business-transformation-and-corporate-update\/","title":{"rendered":"Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update"},"content":{"rendered":"
\n

– Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress <\/p>\n

– PrePsia\u2122 patent portfolio expands to nine granted U.S. and European patents <\/p>\n

– Company issues update on Nasdaq listing<\/p>\n

DUBLIN, Aug. 28, 2026 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, today provided an update on key developments across its diagnostics business, highlighting continued commercial progress, operational transformation and diagnostic pipeline advancement.<\/p>\n

\n Strengthening Commercial Leadership in Europe<\/strong>\n <\/p>\n

Trinity Biotech is pleased to announce that Jordi Romero has joined the Company as Head of Commercial Operations \u2013 Europe. Mr. Romero brings extensive experience in diagnostic sales, marketing and commercial leadership, including significant expertise within the haemoglobin diagnostics market. He joins Trinity at an important stage in the Company’s transformation as it seeks to accelerate profitable growth across its diagnostics franchise in Europe and other international markets.\u00a0<\/p>\n

Mr. Romero’s appointment forms part of Trinity’s broader strategy to strengthen its commercial organisation, deepen customer engagement and enhance execution across key international markets.<\/p>\n

\n Continued Rollout of Upgraded HbA1c Column Technology<\/strong>\n <\/p>\n

The Company also announced continued progress in the commercial rollout of its next-generation high-capacity HbA1c column system for the FDA-cleared Premier Hb9210\u2122 analyser. Trinity has now successfully completed rollout of the upgraded column system in three of its largest international markets and is receiving positive customer feedback regarding performance and overall user experience.<\/p>\n

Designed for Trinity Biotech\u2019s Premier Hb9210\u2122 analyser, the Company\u2019s dedicated laboratory HbA1c solution, the upgraded column system delivers up to four times the testing capacity compared to the existing column system and minimizes instrument downtime through improved stability and reduced calibration requirements. These operational gains create a more efficient workflow for clinical laboratories and support broader adoption of the platform.<\/p>\n

The Company expects continued deployment across additional markets over the coming quarters.<\/p>\n

\n Operational Transformation Driving Margin and Working Capital Benefits<\/strong>\n <\/p>\n

Trinity continues to execute its comprehensive operational transformation programme, including the transition of significant portions of the manufacturing process for its World Health Organization-approved rapid HIV test portfolio to an outsourced manufacturing structure.<\/p>\n

The Company has successfully completed manufacture of the previously announced approximately 9 million TrinScreen HIV tests under this new operating model and has now also commenced manufacture of Uni-Gold\u2122 HIV utilising its outsourced manufacturing structure.<\/p>\n

The Company remains focused on scaling Uni-Gold\u2122 HIV production and has currently a strong order book for the product.<\/p>\n

Once fully scaled, the Company expects the outsourced manufacturing model to deliver meaningful improvements in gross margin performance, manufacturing efficiency and working capital utilisation.<\/p>\n

As previously indicated, the transition and scale-up process may result in quarter-to-quarter variability in Uni-Gold\u2122 HIV revenues during the ramp-up period as manufacturing output continues to increase and supply chain inventories are optimised.<\/p>\n

\n Continued Advancement of the Diagnostics Pipeline <\/strong>\n <\/p>\n

Trinity also continues to advance its pipeline of innovative diagnostic products.<\/p>\n

Most recently, the Company received a European patent covering the use of blood pressure-related metrics in its PrePsia\u2122 early preeclampsia prediction platform. This brings the total number of PrePsia\u2122 related granted patents across Europe and the United States to nine and further strengthens the intellectual property protection around the Company\u2019s maternal health programme.<\/p>\n

PrePsia\u2122 is being developed as an early screening test designed to identify pregnancies at increased risk of preterm preeclampsia, one of the leading causes of maternal and foetal morbidity worldwide. The Company believes the continued expansion of the intellectual property portfolio supporting PrePsia\u2122, and its underpinning technologies, strengthens the foundation for future commercialisation opportunities in women’s health diagnostics.\u00a0<\/p>\n

The Company intends to launch the PrePsia\u2122 test through its existing New York State Department of Health approved reference laboratory.<\/p>\n

\n Transformation Continues to Gain Momentum <\/strong>\n <\/p>\n

The Company believes these achievements demonstrate continued execution against its strategy to transform Trinity Biotech into a more efficient, commercially focused and innovation-driven diagnostics business.<\/p>\n

Key areas of progress include:<\/p>\n